72 results about "Phosphoenolpyruvate carboxykinase" patented technology

The invention relates to isolated nucleotide sequences from Coryneform bacteria which code for the pck gene encoding the enzyme phosphoenol pyruvate carboxykinase (PEP carboxykinase). The invention also relates a process for the fermentative preparation of L-amino acids, in particular L-lysine, L-threonine, and L-glutamate by attenuation of the pck gene.

The present invention relates to a recombinant adenovirus with increased in-vivo safety, tissue specificity, and anticancer activities, and a use thereof. Specifically, the recombinant adenovirus comprising: a promoter of the liver tissue-specific phosphoenolpyruvate carboxykinase (PEPCK) gene; a trans-splicing ribozyme which is operably linked to the promoter and acts on a cancer-specific gene; a therapeutic gene or a reporter gene which is linked to the 3′ exon of the ribozyme; and a serotype 35 fiber knob and a serotype 5 shaft, in which the orf4 gene is deleted from adenovirus E1, E3 and E4 orf1, shows remarkable in-vivo safety, high specificity for a target tissue, and remarkable anticancer effects, and thus can be useful for an anticancer drug or a cancer diagnostic agent as a gene delivery vector.

The invention provides an effective method for improving N-acetylglucosamine (GlcNAc) production by engineered B. subtilis Deletion of phosphoenolpyruvate carboxykinase encoding gene pckA and encoding pyruvate kinase gene pyK in recombinant GlcNAc-producing strain BSGNK-PxylA-glmS-P43-GNA1 (BSGNK) is first performed to enhance GlcNAc production, followed by overexpression of pyruvate carboxylase encoding gene pycA for facilitating cell growth. Finally, the GlcNAc production of the recombinant strain BPTS3 reached to 11.3 g / L, which was 1.84-fold of BSGNK. This method can be used for improve cellular property of engineered B. subtilis for GlcNAc production, which can be further applied to industrial production of GlcNAc.

The invention discloses recombinant escherichia coli for efficiently producing succinic acid and a construction method thereof, and belongs to the technical field of bioengineering. The method comprises the following steps: knocking out a by-product encoding gene of a succinic acid producing strain E.coli FMME-N-2 to obtain a strain E.coli FMME-N-5(delta foc A-pflB-delta ldhA-delta pta-ackA); performing overexpression from actinobacillus succinogenes phosphoenolpyruvate carboxykinase pck and bacillus stutzeri phosphite dehydrogenase ptxD; introducing the constructed plasmid pTrcHisA-pck-ptxD into an expression host E.coli FMME-N-5(delta foc A-pflB-delta ldhA-delta pta-ackA), and screening through an ampicillin resistance flat plate to obtain an engineering bacterium E.coli FMME-N-5(delta foc A-pflB-delta ldhA-delta pta-ackA)-pck-ptx-D for efficiently producing succinic acid. The engineering strain adopts a two-stage fermentation strategy on a 7.5 L fermentation tank, the fermentation time is 96h, the succinic acid yield reaches 137g / L, the succinic acid yield reaches 1g / g glucose, the production strength is 1.43 g / L / h, byproducts lactic acid and formic acid are not accumulated, acetic acid is 1-2g / L, and the engineering strain has certain industrial production potential.

The invention belongs to the field of biotechnology, and discloses a human replication-deficient recombinant adenovirus vector for efficiently expressing leishmania phosphoenolpyruvate carboxykinase (PEPCK) aiming at the current situation of leishmania. Specifically, carrying out homologous recombination on a recombinant vector pShuttle-CMV-Leish-PEPCK constructed by a modified PEPCK gene and a pShuttle-CMV vector and a pAdEasy-1 vector, carrying out PacI cutting on the obtained plasmid vector pAd5-L.m-PEPCK, and transfecting into a human embryo kidney cell 293, so as to obtain the replication-deficient recombinant adenovirus vector Ad5-L.m-PEPCK. Through Coomassie brilliant blue R250 dyeing and Western blot analysis of a specific anti-His tag antibody, it is shown that the recombinant adenovirus vector Ad5-L.m-PEPCK can efficiently express the PEPCK protein. As the leishmania phosphoenolpyruvate carboxykinase (PEPCK) is the most immunodominant leishmania disease antigen which is found recently. Therefore, the recombinant adenovirus vector Ad5-L.m-PEPCK disclosed by the invention can be used for a vaccine for the leishmaniasis, so that the prevention and control of the leishmaniasis are facilitated.

The invention relates to an inorganic phosphorus (phosphate radical) diagnosis / determination kit using the technology of an enzyme colorimetric method and an ELISA method, a method for determining inorganic phosphorus (phosphate radical) concentration and composition and components of a reagent, and belongs to the technical field of test and determination of medical science, food, and environment. The kit comprises the following main components: buffer solution, reduced coenzyme, adenosine diphosphate, oxaloacetic acid, ammonium chloride, potassium chloride, phosphoenolpyruvate carboxykinase, pyruvate kinase, pyruvate dehydrogenase and a stabilizer. The method comprises the following steps: mixing a sample and the reagent according to a certain volume ratio to perform a series of enzymic reaction, and then placing reactants under a UV / visible light analyzer to test the descending speed of absorbance at the position where the dominant wave length is 340nm to determine the inorganic phosphorus (phosphate radical) concentration.

The present invention relates a method for transforming a C3 plant to provide it with a C4 photoshynthetic pathway by way of the introduction of some genes participating in a C4 photosynthetic pathway. To this end, the method of the invention comprises introducing a phosphoenolpyruvate carboxylase (PEPC) and a gene coding for a phosphoenolpyruvate carboxykinase (PCK) which has been connected with a DNA fragment coding for a transit peptide into a C3 plant.

Provided herein are methods, compounds, and compositions for reducing expression of phosphoenolpyruvate carboxykinase-mitochondrial (PEPCK-M) mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preventing or decreasing diabetes, obesity, metabolic syndrome, diabetic dyslipidemia, and / or hypertriglyceridemia in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of diabetes, obesity, metabolic syndrome, diabetic dyslipidemia, and / or hypertriglyceridemia, or a symptom thereof.